EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Predictive Biomarkers and Resistance Mechanisms of Checkpoint Inhibitors in Malignant Solid Tumors

Luciana Alexandra Pavelescu, Robert Mihai Enache, Oana Alexandra Roşu, Monica Profir iD, Sanda Maria Creţoiu iD, Bogdan Severus Gaspar iD

International Journal of Molecular Sciences · 06.09.2024 · 25 (17) · 9659

DOI: 10.3390/ijms25179659 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 06.09.2024. Verfasst von Luciana Alexandra Pavelescu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Morphological Sciences, Cell and Molecular Biology and Histology, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, R…. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Neoplasms, Drug Resistance, Neoplasm, Biomarkers, Tumor. Die Arbeit wurde bisher 57-mal zitiert (Crossref) und nennt 218 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Predictive biomarkers for immune checkpoint inhibitors (ICIs) in solid tumors such as melanoma, hepatocellular carcinoma (HCC), colorectal cancer (CRC), non-small cell lung cancer (NSCLC), endometrial carcinoma, renal cell carcinoma (RCC), or urothelial carcinoma (UC) include programmed cell death ligand 1 (PD-L1) expression, tumor mutational burden (TMB), defective deoxyribonucleic acid (DNA) mismatch repair (dMMR), microsatellite instability (MSI), and the tumor microenvironment (TME). Over the past decade, several types of ICIs, including cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors, anti-programmed cell death 1 (PD-1) antibodies, anti-programmed cell death ligand 1 (PD-L1) antibodies, and anti-lymphocyte activation gene-3 (LAG-3) antibodies have been studied and approved by the Food and Drug Administration (FDA), with ongoing research on others. Recent studies highlight the critical role of the gut microbiome in influencing a positive therapeutic response to ICIs, emphasizing the importance of modeling factors that can maintain a healthy microbiome. However, resistance mechanisms can emerge, such as increased expression of alternative immune checkpoints, T-cell immunoglobulin (Ig), mucin domain-containing protein 3 (TIM-3), LAG-3, impaired antigen presentation, and alterations in the TME. This review aims to synthesize the data regarding the interactions between microbiota and immunotherapy (IT). Understanding these mechanisms is essential for optimizing ICI therapy and developing effective combination strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsNeoplasmsDrug Resistance, NeoplasmBiomarkers, TumorHumansTumor Microenvironment

Stichwörter der Autor:innen

immune checkpoint inhibitorsmicrobiotapredictive biomarkerssolid tumors

Substanzen

Immune Checkpoint InhibitorsBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Morphological Sciences, Cell and Molecular Biology and Histology, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania.
  • Department of Radiology and Medical Imaging, Fundeni Clinical Institute, 022328 Bucharest, Romania.
  • Department of Oncology, Elias University Emergency Hospital, 011461 Bucharest, Romania.
  • Department of Surgery, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania.
  • Surgery Clinic, Bucharest Emergency Clinical Hospital, 014461 Bucharest, Romania.

ORCID-Profile: Monica Profir, Sanda Maria Creţoiu, Bogdan Severus Gaspar

Zitieren

APA

Pavelescu, L. A., Enache, R. M., Roşu, O. A., Profir, M., Creţoiu, S. M., & Gaspar, B. S. (2024). Predictive Biomarkers and Resistance Mechanisms of Checkpoint Inhibitors in Malignant Solid Tumors. International Journal of Molecular Sciences, 25(17), 9659. https://doi.org/10.3390/ijms25179659

Vancouver

Pavelescu LA, Enache RM, Roşu OA, Profir M, Creţoiu SM, Gaspar BS. Predictive Biomarkers and Resistance Mechanisms of Checkpoint Inhibitors in Malignant Solid Tumors. International Journal of Molecular Sciences. 2024;25(17):9659. doi:10.3390/ijms25179659

BibTeX
@article{Pavelescu2024,
  author = {Pavelescu, Luciana Alexandra and Enache, Robert Mihai and Roşu, Oana Alexandra and Profir, Monica and Creţoiu, Sanda Maria and Gaspar, Bogdan Severus},
  title = {Predictive Biomarkers and Resistance Mechanisms of Checkpoint Inhibitors in Malignant Solid Tumors},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  volume = {25},
  number = {17},
  pages = {9659},
  doi = {10.3390/ijms25179659}
}
Kostenlos starten →